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Human T lymphotropic virus type I (HTLV-I) infectsCD4+ T cells and causes adult T-cell leukemia
(ATL) and HTLV-I–associated myelopathy/tropical
spastic paraparesis (HAM/TSP). In addition, several
disorders have been associated with HTLV-I, including
chronic pulmonary disease, chronic renal failure,
uveitis, opportunistic infection, and neoplasmic growth.
Although the precise mechanisms of development are
unclear, these disorders are considered to be manifesta-
tions of HTLV-I–altered cellular immunity.1-8 Two
observations prompted our investigation: (1) symptom-
Objective: Human T lymphotropic virus type I infects CD4+ T cells and
affects cell-mediated immunity. Cardiopulmonary bypass transiently alters
lymphocyte subsets, resulting in a reduction in CD4+ T cells and an increase
in CD8+ T cells. We proposed that cardiovascular operations and human T
lymphotropic virus type I infection may act synergistically, resulting in seri-
ous damage to cell-mediated immunity.
Methods: A total of 517 consecutive patients who were preoperatively
screened for anti-human T lymphotropic virus type I antibody and under-
went cardiovascular operations with cardiopulmonary bypass were enrolled
in this study. Of the 517 patients, 82 (16%) had positive test results for anti-
human T lymphotropic virus type I antibody. The surgical outcome of
patients with positive and negative results for anti-human T lymphotropic
virus type I antibody was analyzed retrospectively.
Results: There was no difference between the 2 groups with respect to early
mortality. Distribution of survival curve was also not significantly different
(P = .5; mean follow-up duration, 2.4 ± 1.8 years [range, 0-9.4 years] and 3.2
± 2.8 years [range, 0-9.8 years]) in the groups with positive and negative
antibody results, respectively). In particular, long-term follow-up did not
reveal adult T-cell leukemia or human T lymphotropic virus type I–associat-
ed myelopathy, and occurrence of neoplasm did not differ between groups.
Early infectious complication was, however, significantly higher in the group
with positive antibody results than in the group with negative results (P =
.02). Logistic regression analysis revealed human T lymphotropic virus type
I infection as a significant risk for this complication (P = .04; odds ratio, 2.5;
95% confidence interval, 1.0-5.8).
Conclusion: A combination of human T lymphotropic virus type I infection
and cardiovascular operation is believed to increase the potential risk of
infectious complications shortly after the operation. However, this synergis-
tic effect seems to be transient and has little influence on long-term progno-
sis. (J Thorac Cardiovasc Surg 2000;120:699-706)
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free carriers of HTLV-I are reported to have subclinical
evidence of impaired cell-mediated immunity,3,4 and
(2) cardiopulmonary bypass (CPB) is known to affect
cellular immunity,9-15 with changes in lymphocyte sub-
sets, including a reduction in CD4+ T cells and an
increase in CD8+ T cells, being common findings.
Therefore, if patients infected with HTLV-I were to
undergo cardiovascular operations, there may be a syn-
ergistic risk of serious damage to cell-mediated immu-
nity, thus increasing susceptibility to infection, neo-
plasms, and other immune disorders. Few studies have
investigated this matter, probably because local HTLV-
I infection is not typically endemic, and thus the patient
pool with HTLV-I is too small. Our institute, however,
is located in the southern Japanese island of Kyushu
where HTLV-I infection is endemic, and we have
observed 219 (15%) HTLV-I carriers in 1470 surgical
patients (including general operations) since 1989. In
the present study we retrospectively investigated the
influence of HTLV-I infection on the outcome of car-
diovascular operations.
Patients and methods
We introduced preoperative screening for the antibody to
HTLV-I by using an enzyme immunoassay (EIA; New Eitest-
ATL; Eisai, Tokyo, Japan) in March 1989. Our subject popu-
lation consisted of 517 consecutive patients who were
screened for anti-HTLV-I antibody between March 1989 and
February 1999. All patients underwent cardiovascular opera-
tions with CPB. Among these patients, 82 (16%) had positive
results for anti-HTLV-I antibody (HTLV-I+), and 435 (84%)
had negative results (HTLV-I–).
Surgery consisted of valve replacement, valvuloplasty,
coronary artery bypass grafting, intracardiac repair of a sim-
ple anomaly, and graft replacement of the thoracic aortic
aneurysm. After systemic heparinization, moderate-to-deep
hypothermic CPB was performed by means of a hollow-fiber
membrane oxygenator. Circulatory arrest with deep
hypothermia or selective cerebral perfusion was used for
cerebral protection in the aortic arch and descending aortic
repair. Myocardial protection was achieved by means of cold
blood cardioplegia, as well as topical myocardial cooling
with cold saline solution. Before discontinuation of CPB, all
patients were warmed to a rectal temperature of 36°C or
more. The heparin effect was neutralized by protamine sul-
fate until the activated coagulation time had normalized.
All postoperative complications were recorded. Cardiac
complications included any heart failure requiring high-dose
catecholamines or mechanical circulatory supports. Pul-
monary complications included all those resulting in pro-
longed mechanical ventilation. Renal complications were
those necessitating hemodialysis. Infectious complication
was defined as any occurrence of mediastinitis, pneumonia,
deep wound infection, or sepsis that necessitated prolonged
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Table I.  Preoperative and operative factors of the patients
Anti-HTLV-I antibody
Variables Positive (n = 82) Negative (n = 435) P value
Age (y) 65 (56-70) 63 (54-69) .2
Weight (kg) 50 (45-59) 53 (47-61) .2
Sex (M/F) 38/44 256/179 .04
Preoperative complications
Diabetes (%) 4 (5) 33 (8) .4
Cerebral infarction (%) 1 (1) 22 (5) .1
Renal failure (%) 2 (2) 13 (3) .8
Pulmonary disease (%) 2 (2)* 4 (1) .2
Neoplasm (%) 1 (1) 7 (2) .8
Others (%) 2 (2) 10 (2) .1
Time of operation
March 1989–February 1995 (%) 40 (49) 259 (60) .1
March 1995–February 1999 (%) 42 (51) 176 (40)
Emergency (%) 8 (10) 25 (6) .2
Redo (%) 2 (2) 18 (4) .8
Procedures
CABG (%) 14 (17) 114 (26) .1
Valve replacement or valvuloplasty (%) 37 (45) 183 (42) .6
Intracardiac repair of anomaly (%) 8 (10) 45 (10) .9
Repair of thoracic aortic aneurysm (%) 17 (21) 71 (16) .3
Others (%) 6 (7) 22 (5) .4
CPB time (min) 147 (108-188) 150 (122-187) .3
Aortic crossclamp time (min) 93 (67-126) 88 (71-116) .9
Data are given as median (25th-75th percentile) where shown. CABG, Coronary artery bypass grafting.
*Includes a patient with suspected HTLV-I–associated bronchopneumonopathy.
antibiotic therapy. Early morbidity and mortality were
defined as complication or death occurring during the admis-
sion period after an operation. Any event occurring after dis-
charge was defined as a late event. Follow-up information
was obtained by reviewing patient medical records or by
direct telephone contact. Questions were asked about the
cause and date of death, the patient’s condition, autonomy,
medical treatment, and whether any signs of myelopathy,
uveitis, or respiratory disorders were present. Mean follow-
up duration was 2.4 ± 1.8 years (range, 0-9.4 years) for
HTLV-I+ patients and 3.2 ± 2.8 years (range, 0-9.8 years) for
HTLV-I– patients.
All statistical analyses were conducted by means of JMP
Statistical Discovery Software (SAS Institute, Inc, Cary, NC).
Data are expressed as median and 25th and 75th percentiles.
Differences between the groups were determined by the
Mann-Whitney U test and the Fisher exact test. Survival data
were analyzed by standard Kaplan-Meier actuarial tech-
niques for estimation of survival probability. We also exam-
ined the early and late postoperative events to analyze the
temporal relation between operations and manifestation of
HTLV-I infection. However, this analysis, especially for late
events, is limited in its interpretation because these events are
time-related subjects and are too diverse to be dealt with as
simple proportions. In addition, the present study is not ran-
domized and involves a problem of dissimilarities of the
groups. Because of these limitations and risks, we also exam-
ined the influences of preoperative and operative risk factors
on surgical outcomes with a logistic regression analysis.
This study was conducted along with guidelines for human
research by the Ethics Committee at Kagoshima University
Faculty of Medicine, and informed consent was obtained
from all patients.
Results
Background factors, including age, body weight, and
preoperative complications, were similar for both
HTLV-I+ and HTLV-I– groups, although the proportion
of female subjects was significantly larger in the HTLV-
I+ group than in the HTLV-I– group. The data also
included an HTLV-I+ patient with suspected HTLV-
I–associated bronchopneumonopathy. Moreover, the
time of the operation, emergency or redo status, proce-
dures, duration of CPB, and aortic crossclamping were
also similar between the 2 groups (Table I).
Early mortality did not differ significantly between
the 2 groups (5/82 HTLV-I+ patients (6%) and 29/435
HTLV-I– patients (7%), P = .9). There was no signifi-
cant difference in the distribution of causes of early
death, such as cerebrovascular accident, heart failure,
and sepsis, although a case of graft versus host disease
(GVHD) was observed in the HTLV-I+ group (Table II).
Early complications occurred in 24 (29%) of 82
patients in the HTLV-I+ group compared with 77 (18%)
of 435 patients in the HTLV-I– group. This difference
was statistically significant (P = .02). In particular, the
occurrence of infectious complications was significant-
ly higher in the HTLV-I+ group than in the HTLV-I–
group (P = .02). The other complications, heart failure,
cerebrovascular accident, renal failure, and respiratory
failure, occurred without significant differences bet-
ween the groups (Table II).
The factors thought to be risks for infection, such as
age, sex, diabetes, renal failure, and conditions of the
operation, including HTLV-I infection, were then
examined by logistic regression analysis. This revealed
anti-HTLV-I antibody positivity as the only significant
risk factor for infectious complication (P = .04; odds
ratio [OR], 2.5; 95% confidence interval [CI], 1.0-5.8).
Emergency status tended to be another risk (P = .07;
OR, 1.6; 95% CI, 0.8-7.2). The other factors did not
exert significant influences on this complication.
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Table II.  Early death and complication
Anti-HTLV-I antibody
Positive (n = 82) Negative (n = 435) P value
Causes of death (%) Cerebrovascular accident 2 (2.5) 6 (1.4) .2
Heart failure 0 (0) 12 (2.8) .1
Infection* 1 (1.2) 5 (1.1) .9
Multiple organ failure 1 (1.2) 3 (0.7) .6
Others 1 (1.2)† 3 (0.7) .6
Complications (%) Infection* 8 (9.7) 17 (3.9) .02
Heart failure 2 (2.4) 18 (4.1) .5
Cerebrovascular accident 2 (2.4) 13 (3.0) .8
Respiratory failure 3 (3.7) 7 (1.6) .2
Renal failure 2 (2.4) 5 (1.1) .4
Others 7 (8.5) 17 (3.9) .07
*Infection indicates mediastinitis, sepsis, pneumonia, or deep wound infection.
†A case of GVHD.
There was no significant difference in the microor-
ganisms identified for the 2 groups (P = .8).
Methicillin-resistant Staphylococcus aureus was a
major causative microorganism in both groups, affect-
ing 4 (50%) of 8 HTLV-I+ patients and 9 (52%) of 17
HTLV-I– patients. As to fungus infection, correspond-
ing figures were 1 (13%) of 8 patients and 1 (6%) of 17
patients, respectively.
Because late events were influenced by many time-
related factors, we described only the proportion of
events (Table III). Late death was observed in 7 of 77
patients in the HTLV-I+ group and 25 of 406 patients in
the HTLV-I– group. The major cause of late death was
cardiac event in each group, and composition of the
causes was similar between the groups (P = .3). There
was no significant difference in distribution of late sur-
vival between the HTLV-I+ and the HTLV-I– groups
(Fig 1; P = .5; 2.5 ± 1.6 vs 3.4 ± 2.8 follow-up years,
respectively). Late complications occurred in 3 of 77
patients in the HTLV-I+ group and 13 of 406 patients in
the HTLV-I– group. In the HTLV-I+ group ATL,
HAM/TSP, or uveitis was not seen. There was no sig-
nificant difference in late complication (P = .3).
Distribution of the event-free curve was also similar
between the groups (Fig 2; P = .2; 2.6 ± 1.7 vs 3.4 ± 2.8
follow-up years, respectively).
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Fig 1. Late survival of HTLV-I+ and HTLV-I– groups. Early deaths are not included. Follow-up durations are
expressed as means and SD (a and b) and medians with 25th to 75th percentiles, respectively. Difference of distri-
butions between the 2 groups was not significant (P = .5).
Table III.  Late death and complication
Anti-HTLV-I antibody Positive Negative P value
Causes of death (%) Cardiac events 5 (72) 8 (32) .3
Cerebrovascular accident 1 (14) 5 (20)
Neoplasm 1 (14) 1 (4)
Infection 0 (0) 5 (20)
Aneurysmal rupture 0 (0) 3 (12)
Unknown 0 (0) 3 (12)
Total 7 (100) 25 (100)
Complications (%) Cerebrovascular accident 1 (33) 2 (15) .3
Neoplasm 0 (0) 3 (23)
Pulmonary disease 0 (0) 3 (23)
Exaggeration 2 (67) 2 (15)
Others 0 (0) 3 (23)
Total 3 (100) 13 (100)
Ten risk factors, including age, body weight at the
operation, sex, anti-HTLV-I antibody positivity, dia-
betes mellitus, renal failure, time of the operation,
emergency or redo status, and CPB time were exam-
ined by logistic regression analysis (Table IV).
Emergency status was a major risk for early death 
(P < .01; OR, 8.4; 95% CI, 3.2-21.8) and early compli-
cation (P < .01; OR, 3.2; 95% CI, 1.4-6.9).
Interestingly, the analysis showed anti-HTLV-I anti-
body positivity also as a significant risk for early com-
plication (P < .01; OR, 2.2; 95% CI, 1.2-4.0). There
was no significant risk concerning late death. Causative
risk for late complication was only redo operation (P =
.03; OR, 10.6; 95% CI, 1.3-89.2).
There were 2 cases in which HTLV-I involvement
was suspected. A 68-year-old man in whom HTLV-
I–associated bronchopneumonopathy was suspected
before the operation had respiratory distress, and
analysis showed he had a high titer level of anti-HTLV-
I antibody. In addition, atypical lymphocytes similar to
ATL cells appeared in his peripheral blood. He had no
further development of disease and his condition
remained stable for 3.3 years after coronary artery
bypass grafting. Another patient was a 24-year-old
woman who died of GVHD 32 days after aortic and
mitral valve replacement. She and her parents were
HTLV-I carriers. In the HLA typing with her parents
and sister, 2 unmatched antigens of class II were exhib-
ited in her lymphocyte sample, but all class I antigens,
which are usually involved in posttransfusion GVHD,
were matched. In addition, Y-chromatin was not detect-
ed in her lymphocytes, and pancytopenia was not
proven (data not shown).
Discussion
HTLV-I carrier population is usually 0.02% to 0.04%
in nonendemic areas. In regions where it is endemic,
such as the southern Japanese island of Kyushu, it is
12% to 27%.3,16,17 Our institute is located in this area,
and the HTLV-I carrier population is 15%. This high
prevalence made it possible to observe sufficient num-
bers of HTLV-I carriers to permit statistical analysis.
Because EIA screening could generate both false-
positive and false-negative results, HTLV-I infection
was usually confirmed by Western blotting.16,17
Together with improved purification of the HTLV-I
antigen and improved methods, the difference between
recent EIA and Western blotting has been reduced. The
sensitivity and specificity of the EIA used in the pre-
sent study is reportedly 100% and 99% to 100%,
respectively.18 Although we could not apply the 2-step
method in this study, the diagnostic results are consid-
ered to be comparable with those of Western blotting.
As forementioned, this study is not randomized and
involves a risk of dissimilarities between the 2 groups.
Actually, female dominance in HTLV-I+ patients was
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Fig 2. Event-free survival of HTLV-I+ and HTLV-I– groups. Early complications are not included. Follow-up durations
are expressed as means and SD (a and b) and medians with 25th to 75th percentiles, respectively. Difference of dis-
tributions between the 2 groups was not significant (P = .2).
significant. Therefore, the limitation deriving from dis-
similarities of the HTLV-I+ and HTLV-I– group should
be taken into account when comparing the 2 groups.
We then analyzed the influence of sex by the logistic
regression test and found that it had little effect on the
surgical outcome. The female dominance is correspon-
dent with previous reports. Although the high mortality
of male carriers may cause it, the precise mechanism is
still not known.
Previous reports have indicated subclinical evidence
of impaired cell-mediated immunity in asymptomatic
HTLV-I carriers.3,4 HTLV-I–infected CD4+ T cells
express viral epitopes in the context of their major his-
tocompatibility complex (MHC) class I, which activate
MHC class I–restricted antiviral CD8+ cytotoxic T
cells.6 Bernal and colleagues3 hypothesized that the
activated CD8+ T cells suppress the infected CD4+ T
cells or, alternatively, that HTLV-I directly decreases
the proliferative potential of CD4+ T cells, such as
occurs in acquired immunodeficiency syndrome.
Consequently, lymphocyte subsets may be altered by a
reduction in the CD4+ T-cell count and an elevation in
the CD8+ T-cell count.
We must also consider how the immune system is
affected under such circumstances. CPB is known to
induce alterations in cell-mediated immunity, a
reduction in CD4+ T cells, an increase in CD8+ T
cells, and a decrease in natural killer cell cytotoxic
activity.9-15 Alterations are common but transient,
generally lasting only 3 to 4 days postoperatively.9-15
However, this temporal effect may be crucial to the
CD4+ and CD8+ T cells already infected by HTLV-I.
Under this assumption, synergistic impairment of the
immune system should appear during the early post-
operative period. In the present study the incidence of
infectious complications, such as sepsis, mediastini-
tis, deep wound infection, and pneumonia, were sig-
nificantly higher in the HTLV-I+ group. In addition,
risk factors except anti-HTLV-I antibody positivity
and emergency status could not reveal significant
influences on the infectious complication through
logistic regression analysis. Although methicillin-
resistant Staphylococcus aureus was the major
microorganism seen, fungus was also observed. On
the other hand, there was no significant influence of
HTLV-I infection on late mortality and morbidity.
These findings suggest a temporary impairment in
immune response. Further examination into perioper-
ative alterations of lymphocyte subsets in HTLV-I+
patients is necessary to clarify the precise process.
Individuals infected with HTLV-I reportedly have an
estimated 4% lifetime risk of either ATL or
HAM/TSP.19 However, the precise mechanism through
which neurologic symptoms, another a neoplastic con-
dition, develop in 1 group of HTLV-I+ individuals while
the majority remain asymptomatic remains unclear.5,7
Incidence of ATL development is only about 1 of
1200 carriers every year. In addition, it generally takes
about 50 years for an asymptomatic HTLV-I carrier to
manifest overt ATL.8 To date, there have been no
reports of this type of leukemia developing after a car-
diovascular operation in HTLV-I+ patients. On the other
hand, manifestation of ATL under long-term immuno-
suppressive therapy has been reported in renal trans-
plantation.8 The authors proposed that immunosup-
pression shortens the duration of the asymptomatic
carrier state. Thus, severe and sustained immune
impairment appears to be an important factor in the
progression of adult T-cell leukemia.
Two cases of HAM/TSP have been reported.20
These patients manifested HAM/TSP 1 and 2 years
after their cardiac operations, respectively. Although
preoperative HTLV-I infection was not addressed, the
authors proposed that the cause of infection was allo-
704 Masuda et al The Journal of Thoracic and
Cardiovascular Surgery
October 2000
Table IV.  Logistic regression analysis of risk factors for early and late events
Early death Early complication
Variables OR (95% CI) P value OR (95% CI) P value
Age (y) 1.1 (0.7-1.7) .02 1.0 (1.0-1.1) <.01
Body weight (kg) 1.0 (0.6-1.5) .2 1.0 (1.0-1.0) .2
Sex (M/F) 0.6 (0.3-1.6) .3 0.8 (0.4-1.3) .3
HTLV-I (positive/negative) 0.9 (0.3-2.8) .9 2.2 (1.2-4.0) <.01
Diabetes (yes/no) — — 0.6 (0.3-1.2) .1
Renal failure (yes/no) 0.5 (0.2-1.0) .06 1.9 (1.1-3.4) .03
Time of operation (≤February 1995/March 1995≤) 0.3 (0.1-0.8) .02 0.7 (0.4-1.2) .2
Emergency operation (yes/no) 8.4 (3.2-21.8) <.01 3.1 (1.4-6.9) <.01
Redo operation (yes/no) 2.4 (0.4-13.8) .3 1.3 (0.3-4.5) .7
CPB time (min) 1.0 (1.0-1.0) <.01 1.0 (1.0-1.0) <.01
Diabetes and renal failure are preoperative complications. —, Variables are unstable for analysis.
genic HTLV-I+ blood transfusion. Before the intro-
duction of HTLV-I screening, we experienced a sim-
ilar case in which the patient developed HAM/TSP 1
year after mitral valve replacement (not reported).
Because seroconversion to HTLV-I actually occurs
after allogenic blood transfusion, HTLV-I may have
caused HAM/TSP in these patients.16,17 However,
whether HAM/TSP develops in HTLV-I carriers after
an operation remains unclear. In the present study a
patient with suspected HTLV-I–associated broncho-
pneumonopathy showed no progression of disease
for 3.3 years. Overall, progression of HTLV-I–associ-
ated disorders does not appear to occur frequently in
HTLV-I+ cardiovascular operations.
GVHD typically occurs because of allogenic blood
transfusion and has the following characteristic fea-
tures: new antigen appearance in HLA class I antigen,
pancytopenia, and occasional acquisition of Y-chro-
matin in female patients. Our patient exhibited neither
pancytopenia nor Y-chromatin, but 2 unmatched anti-
gens of class II in the patient’s lymphocyte sample
were observed. These findings appear to differ from
typical post-transfusion GVHD. HTLV-I is known to
express alien antigens to the MHC on the lymphocyte.
Graft-versus-host reaction was subsequently proposed
to be induced by HTLV-I, which was activated to pro-
voke the alien HLA antigens under the immunocom-
promised state.21 We have encountered only 1 GVHD
case (1.2%) of 82 HTLV-I+ cardiovascular surgical
patients (1 [0.46%] of 219 HTLV-I+ surgical patients).
The frequency of GVHD is higher than that of post-
transfusion GVHD. However, there are few reports of
such GVHD cases in the literatures. We cannot com-
ment further about this matter with little experience
and no supportive reports.
In conclusion, the combination of HTLV-I infection
and a cardiovascular operation appears to increase
the risk of infectious complications in the early post-
operative period. However, this synergistic effect
seems to be transient and has little influence on long-
term prognosis.
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